Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death-1 (PD1, PD-1)”

245 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 245 results

Post-approval studies (Phase 4)Study completedNCT04489888
What this trial is testing

Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Merck Sharp & Dohme LLC 101
Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Large-scale testing (Phase 3)Study completedNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 479
Not applicableNot Yet RecruitingNCT07643688
What this trial is testing

Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections

Who this might be right for
SARS CoV 2 InfectionRSV InfectionsInfluenza Infection
Fabiana Sherine Ganem dos Santos 150
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Testing effectiveness (Phase 2)UnknownNCT04911517
What this trial is testing

Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

Who this might be right for
Colorectal Neoplasms
Beijing Friendship Hospital 50
Testing effectiveness (Phase 2)Study completedNCT02674061
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Who this might be right for
Ovarian Neoplasms
Merck Sharp & Dohme LLC 376
Large-scale testing (Phase 3)Study completedNCT03833167
What this trial is testing

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Who this might be right for
Carcinoma, Squamous Cell
Merck Sharp & Dohme LLC 450
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 130
Large-scale testing (Phase 3)Study completedNCT01905657
What this trial is testing

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 1,034
Testing effectiveness (Phase 2)Looking for participantsNCT05319730
What this trial is testing

Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 230
Large-scale testing (Phase 3)Study completedNCT03976323
What this trial is testing

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Who this might be right for
Carcinoma, Nonsquamous Non-small-cell Lung
Merck Sharp & Dohme LLC 1,003
Testing effectiveness (Phase 2)Ended earlyNCT03769467
What this trial is testing

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Who this might be right for
Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsEpstein-Barr Virus Infections+2 more
Atara Biotherapeutics 12
Large-scale testing (Phase 3)Study completedNCT02358031
What this trial is testing

Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Who this might be right for
Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
Merck Sharp & Dohme LLC 882
Testing effectiveness (Phase 2)Looking for participantsNCT06712875
What this trial is testing

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Who this might be right for
Low Grade GliomaHigh Grade Glioma
Ann & Robert H Lurie Children's Hospital of Chicago 27
Large-scale testing (Phase 3)Active Not RecruitingNCT05239728
What this trial is testing

Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,800
Testing effectiveness (Phase 2)Active Not RecruitingNCT02628067
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Who this might be right for
Advanced CancerAnal CarcinomaAnal Cancer+22 more
Merck Sharp & Dohme LLC 1,609
Large-scale testing (Phase 3)Study completedNCT03635567
What this trial is testing

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Who this might be right for
Cervical Cancer
Merck Sharp & Dohme LLC 617
Large-scale testing (Phase 3)Study completedNCT03976375
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 422
Large-scale testing (Phase 3)Study completedNCT03898180
What this trial is testing

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Who this might be right for
Urothelial Carcinoma
Merck Sharp & Dohme LLC 505
Load More Results